Format

Send to

Choose Destination
See comment in PubMed Commons below
Breast Cancer (Dove Med Press). 2012 May 23;4:75-81. doi: 10.2147/BCTT.S16356.

Decreased risk of breast cancer associated with oral bisphosphonate therapy.

Author information

  • 1Department of Internal Medicine, University of Pittsburgh Medical Center, USA.
  • 2Division of Hematology/Oncology, Magee-Womens Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.

Abstract

Preclinical studies and adjuvant trials using bisphosphonates have found them to have an antitumor effect. Although major advances have been made in chemoprevention strategies with selective estrogen receptor modulators and aromatase inhibitors, their use has been fraught with significant adverse effects such as venous thromboembolic events and an increased risk for endometrial cancer. In this context, several recent observational studies have investigated a chemoprevention role for oral bisphosphonates in decreasing risk for breast cancer. This review will aim to summarize these studies and present a critical evaluation of the association between oral bisphosphonate use and breast cancer risk reduction.

KEYWORDS:

alendronate; chemoprophylaxis; incidence; risk reduction; zoledronate

PMID:
24367195
PMCID:
PMC3846467
DOI:
10.2147/BCTT.S16356

Publication Types

Publication Types

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center